Integrative Biomedical Research
Integrative Biomedical Research (Journal of Angiotherapy) | Online ISSN 3068-6326
463
Citations
1.9m
Views
779
Articles
Volume 10 Number 2 2026
REVIEWS (Open Access)
Oral Insulin and GLP-1 Receptor Agonist Delivery Technological Advances and Physiological Barriers Toward Non-Invasive Diabetes Therapeutics
Gnanasekaran Ashok 1*, Diksha D Shroff 2, Lubna Shirin 3, Pugazhandhi Bakthavatchalam 4
Integrative Biomedical Research 10 (2) 1-8 https://doi.org/10.25163/biomedical.10210939
Submitted: 11 September 2026 Revised: 01 November 2026 Accepted: 08 November 2026 Published: 10 November 2026
Abstract
Subcutaneous injection still dominates insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, and honestly, it shows: needle-related pain, lipodystrophy, and non-adherence continue to blunt the real-world benefit of otherwise excellent molecules. This review asks a fairly simple question with a stubbornly complicated answer — can these biologics be swallowed instead of injected, and if so, how close are we? We synthesized recent formulation, device, and clinical literature (2023-2026) describing oral and transmucosal delivery of insulin and GLP-1RAs. Across the gastrointestinal tract, peptides confront a near-continuous gauntlet: gastric acid and pepsin, pancreatic and brush-border proteases, a viscoelastic mucus mesh, tight-junction-sealed epithelium, and, for whatever survives, hepatic first-pass extraction — together limiting unformulated bioavailability to well under 1%. Four broad engineering responses have emerged. Chemical permeation enhancers such as salcaprozate sodium (SNAC) and ionic liquids transiently fluidize membranes, underpinning the only currently approved product, oral semaglutide (Rybelsus®), though its bioavailability remains near 1% and its chronic gut-microbiota effects warrant continued scrutiny. Lipid, polymeric, zwitterionic, and transporter-targeted nanocarriers push relative bioavailability toward the 4-27% range in preclinical models. Ingestible micro-injectors (SOMA, LUMI), buccal and sublingual films, and engineered probiotic secretory depots bypass the gut lumen almost entirely. Meanwhile, non-peptide small-molecule GLP-1RAs sidestep the degradation problem altogether, reaching 20-30% oral bioavailability without enhancers. Taken together, the field has moved from proof-of-concept toward genuinely translatable platforms, though variable inter-subject absorption, excipient safety, and manufacturing scalability remain open questions. We argue that no single strategy is likely to “win” outright; rather, combinatorial and indication-specific approaches will probably define the next generation of non-invasive diabetes biologics.
Keywords: Oral insulin delivery; GLP-1 receptor agonists; peptide permeation enhancers; nanocarrier drug delivery; gastrointestinal barriers; oral bioavailability; diabetes mellitus
References
Abdullahi, A. D., Ibrahim, M. A., & Serem, J. C. (2026). Peptide delivery in the management of diabetes: Exploring bioinspired nanoarchitectures using stimuli-responsive materials and supramolecular depots. International Journal of Pharmaceutics, 701, Article 127169. https://doi.org/10.1016/j.ijpharm.2026.127169
Al Tahan, M. A., Al-Khattawi, A., & Russell, C. (2025). Oral peptide delivery systems: Synergistic approaches using polymers, lipids, nanotechnology, and needle-based carriers. Journal of Drug Delivery Science and Technology, 112, Article 107205. https://doi.org/10.1016/j.jddst.2025.107205
Ariaee, A., Noueihad, K., Hunter, A., Wignall, A., Wardill, H. R., Davies, M., Prestidge, C. A., & Joyce, P. (2026). The degree of inulin polymerization is important for short-term amelioration of high-fat diet (HFD)-induced metabolic dysfunction and gut microbiota dysbiosis in rats. Journal of Controlled Release, 392, Article 114711. https://doi.org/10.1016/j.jconrel.2026.114711
Beloqui, A. (2024). Gut hormone stimulation as a therapeutic approach in oral peptide delivery. Journal of Controlled Release, 373, 31–37. https://doi.org/10.1016/j.jconrel.2024.07.007
Chen, C.-J., Wong, M.-T., Yu, Y.-H., Chu, H.-M., Lim, C., & Chang, T. W. (2026). Optimized sublingual delivery of dual fatty acid–conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice. International Journal of Pharmaceutics, 694, Article 126752. https://doi.org/10.1016/j.ijpharm.2026.126752
Huang, Y., Lin, X., Deng, M., Tang, Y., Li, S., Xu, B., Zeng, W., Chen, Z., Hou, X., Lin, Z., Meng, X., Bai, Y., Fan, H., & Zeng, W. (2026). Oral delivery of GLP-1 analogues by recombinant Lactococcus lactis restores pancreatic islet structure through intestinal mucosal absorption in diabetic mice. eBioMedicine, 124, Article 106141. https://doi.org/10.1016/j.ebiom.2026.106141
Nabi-Afjadi, M., Ostadhadi, S., Liaghat, M., Pasupulla, A. P., Masoumi, S., Aziziyan, F., Zalpoor, H., Abkhooie, L., & Tarhriz, V. (2024). Revolutionizing type 1 diabetes management: Exploring oral insulin and adjunctive treatments. Biomedicine & Pharmacotherapy, 176, Article 116808. https://doi.org/10.1016/j.biopha.2024.116808
Ozesme Taylan, G., Illanes-Bordomás, C., Guven, O., Erkan, E., Çikrikci Erünsal, S., Oztop, M. H., & García-González, C. A. (2025). Core-shell aerogel design for enhanced oral insulin delivery. International Journal of Pharmaceutics, 669, Article 125038. https://doi.org/10.1016/j.ijpharm.2024.125038
Pantazoglou, E., Bahuon, F., Andresen, A. K., Tollemeto, M., Zhang, Z., Tzitzigiannis, I., Ezazi, N. Z., Sacramento, M. M. A., Mano, J. F., Untracht, G. R., Andersen, P. E., van de Weert, M., Berthelsen, R., Buckley, S. T., Hosta-Rigau, L., Jacobsen, J., & Nielsen, L. H. (2026). Layer-by-layer polymeric films for buccal GLP-1 delivery. Cell Reports Physical Science, 7, Article 103410. https://doi.org/10.1016/j.xcrp.2026.103410
Qi, W., Boca, S. M., Boianelli, A., Fredberg, M., Lundqvist, S., Davies, G., Field, J., Brighton, C. A., Snijder, A., Grundevik, P., Eckernäs, D., Träff, A. M., Polla, M., Pettersen, D., Omar, S., Hansen, L., Janzén, D., Melin, J., van Zuydam, N., Logue, J., & Wallenius, K. (2025). Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist. The Journal of Pharmacology and Experimental Therapeutics, 392, Article 103683. https://doi.org/10.1016/j.jpet.2025.103683
Rabbani, S. A., Saini, M., El-Tanani, M., Kumar, R., Matalka, I., El-Tanani, Y., Sharma, S., & Rizzo, M. (2026). Oral GLP-1-based therapeutics in the obesity–metabolic syndrome–diabetes continuum: Translational advances, clinical barriers, and emerging strategies. Pharmaceuticals, 19(5), Article 732. https://doi.org/10.3390/ph19050732
Rebollo, R., Xiao, Z., Blaabjerg, L., La Zara, D., Juel, T., Pedersen, H. D., Andersson, V., Benova, M., Krogh, C., Pons, R., Holm, T. P., Wahlund, P.-O., Fan, L., Wang, Z., Kennedy, A., Kuhre, R. E., Christophersen, P., Bardonnet, P.-L., & Sassene, P. J. (2025). Salcaprozate-based ionic liquids for GLP-1 gastric delivery: A mechanistic understanding of in vivo performance. Journal of Controlled Release, 377, 267–276. https://doi.org/10.1016/j.jconrel.2024.11.036
Su, J., Xu, J., Hu, S., Ye, H., Xie, L., & Ouyang, S. (2024). Advances in small-molecule insulin secretagogues for diabetes treatment. Biomedicine & Pharmacotherapy, 178, Article 117179. https://doi.org/10.1016/j.biopha.2024.117179
Subedi, L., Bamjan, A. D., Kim, E., Phuyal, S., Sapkota, B., Kim, K.-T., Cho, S.-S., Shim, J.-H., Seo, J. B., & Park, J. W. (2026). Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes. Journal of Controlled Release, 399, Article 115297. https://doi.org/10.1016/j.jconrel.2026.115297
Subedi, L., Bamjan, A. D., Phuyal, S., Shim, J.-H., Cho, S.-S., Seo, J. B., Chang, K.-Y., Byun, Y., Kweon, S., & Park, J. W. (2025). An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits. Journal of Controlled Release, 378, 637–655. https://doi.org/10.1016/j.jconrel.2024.12.039
Wang, Q., Guo, H., Mao, W., Qian, X., & Liu, Y. (2023). The oral delivery system of modified GLP-1 by probiotics for T2DM. Pharmaceutics, 15(4), Article 1202. https://doi.org/10.3390/pharmaceutics15041202
Wong, C. Y. J., Baldelli, A., Tietz, O., Leite, E., Ong, H. X., & Traini, D. (2025). Delivery of insulin via the intranasal route: Advantages, barriers, and formulation strategies. International Journal of Biological Macromolecules, 332, Article 148663. https://doi.org/10.1016/j.ijbiomac.2025.148663
Ziebarth, J., Babinski, T. P., Moreira, F. F., Tartari, A. P. S., Zago, A., da Costa, S. P., Pinheiro, M. F., & Mainardes, R. M. (2026). Preparation, characterization and in vitro evaluation of hybrid zein-Eudragit RS100-chitosan nanoparticles for the co-delivery of insulin and liraglutide (Z-ERS-CS/I-LIRA). International Journal of Biological Macromolecules, 375, Article 153507. https://doi.org/10.1016/j.ijbiomac.2026.153507
Recommended articles
Obesity Pharmacotherapy in the GLP-1 Era: Efficacy, Equity, and the Long-Term Unknowns of Incretin-Based Care
Modifiable Triggers and Autoimmune Disease Flares: A Mechanistic and Clinical Synthesis of Molecular Mimicry, Barrier Disruption, and Neuroendocrine-Microbial Crosstalk
Early Prediction of Postprandial Glycemic Response in Gestational Diabetes Using Continuous Glucose Monitoring and Gradient Boosting Models
Article metrics
View details
0
Downloads
0
Citations
26
Views
0
Save
Save
0
Citation
Citation
26
View
View
0
Share
Share